MiNK Therapeutics, Inc. (INKT)

MiNK Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	1.68	4.58	3.37	19.64	38.89	2.69
Cash & Short-Term Investments	1.68	4.58	3.37	19.64	38.89	2.69
Cash Growth	-81.94%	35.93%	-82.85%	-49.51%	1345.06%	799.94%
Other Receivables	-	-	-	-	-	0.25
Receivables	-	-	-	-	-	0.25
Prepaid Expenses	0.27	0.25	0.05	0.3	0	0.49
Other Current Assets	0.06	0.16	0.18	0.47	0.74	0.66
Total Current Assets	2.01	4.99	3.6	20.4	39.63	4.1
Property, Plant & Equipment	0.47	0.73	0.95	1.07	0.61	0.46
Total Assets	2.48	5.72	4.55	21.47	40.24	4.56
Accounts Payable	3.31	2.73	3.91	5.82	3	3.14
Accrued Expenses	1.86	1.87	5.04	4.24	1.76	1.86
Other Current Liabilities	2.48	2.36	2.45	2.62	11.71	9.22
Total Current Liabilities	13.16	6.96	11.4	12.68	16.47	14.22
Long-Term Debt	-	4.92	-	-	-	43.82
Other Long-Term Liabilities	14.51	13.42	11.21	9.19	-	0.38
Total Liabilities	27.67	25.31	22.61	21.87	16.47	58.43
Common Stock	0	0	0	0	0	0
Additional Paid-In Capital	126.72	125.23	115.77	110.83	107.35	0.38
Retained Earnings	-151.19	-144.18	-133.4	-110.94	-82.95	-52.74
Comprehensive Income & Other	-0.72	-0.63	-0.43	-0.29	-0.63	-1.52
Shareholders' Equity	-25.19	-19.59	-18.06	-0.4	23.78	-53.87
Total Liabilities & Equity	2.48	5.72	4.55	21.47	40.24	4.56
Total Debt	5.51	4.92	-	-	-	43.82
Net Cash (Debt)	-3.82	-0.35	3.37	19.64	38.89	-41.13
Net Cash Growth	-	-	-82.85%	-49.51%	-	-
Net Cash Per Share	-0.96	-0.09	0.98	5.83	14.94	-17.06
Filing Date Shares Outstanding	4.52	3.97	3.47	3.39	3.36	2.42
Total Common Shares Outstanding	3.99	3.96	3.46	3.39	3.35	2.42
Working Capital	-11.15	-1.97	-7.8	7.72	23.17	-10.13
Book Value Per Share	-6.31	-4.94	-5.22	-0.12	7.10	-22.28
Tangible Book Value	-25.19	-19.59	-18.06	-0.4	23.78	-53.87
Tangible Book Value Per Share	-6.31	-4.94	-5.22	-0.12	7.10	-22.28
Machinery	1	1.26	1.45	1.35	0.78	0.56

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q